November 7, 2016
Fitch Even partner Paul B. Henkelmann was quoted in an article published online in last week’s edition of Chemical & Engineering News, a publication of the American Chemical Society.
The article, titled "Hedge Fund Manager Wins U.S. Drug Patent Challenges," discusses recent Patent Trial and Appeal Board rulings that invalidated claims of a Shire PLC patent covering its drug Gattex and claims of two Celgene Corp. patents related to the cancer drugs Thalomid, Revlimid, and Pomalyst. The Coalition for Affordable Drugs, an organization started by hedge fund manager Kyle Bass, had challenged the validity of these patents, among others.
- IP Alert | USPTO Releases Latest Guidance for Evaluating Subject Matter Eligibility Under 35 U.S.C. § 101January 11, 2019 Read more
- IP Alert | USPTO Releases Guidance for Examining Computer-Implemented Functional Claim Limitations for Compliance with 35 U.S.C. § 112January 11, 2019 Read more